NeoGenomics Announces Participation in NCI-MATCH Clinical Trial

NeoGenomics Awarded Clinical Reference Laboratory Testing Services Agreement with Premier

Jul 24, 2018 • 7:00 AM EDT

Q2 2018 Quarterly Results

Quarter Ended Jun 30, 2018

9% increase in consolidated revenue; 12% excluding PathLogic

14% increase in clinical genetic testing volume

22% increase in Pharma Services revenue

95% increase in Pharma Services backlog

2018 Second Quarter Conference Call

July, 24 2018 • 8:30 AM ET

PPD and NeoGenomics Forming Global Strategic Alliance for Pathology and Molecular Testing Solutions

Company Profile

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.

Latest Quarterly Results

Q2 2018

Quarter Ended Jun 30, 2018

Latest 10-K

View Latest 10-K

NeoGenomics, Inc.

Nasdaq: NEO





Day Range

52 week Range

IR Contact Information

Investor Relations William Bonello
Chief Strategy and Corporate Development Officer
Director, Investor Relations
T: (239) 690-4238
M: (239) 284-4314

Transfer Agent Standard Registrar & Transfer Company
12528 South 1840 East
Draper, UT 84020
T: (801) 571-8844